CEL-SCI Expands H1N1 Flu Virus Work(makes it possible to 1) program the inte...),Health

Date:8/18/2009

makes it possible to 1) program the intended immune response and 2) avoid the administration of regions of the H1N1, and other viruses, that may exacerbate the problem of cytokine storm. Cytokine storm is very much involved in the death of many H1N1 patients.

The L.E.A.P.S. technology combines a small peptide that activates the immune system with a small peptide from a disease-related protein, such as the H1N1 hemagglutinin molecule, to make a vaccine that induces a defined immune response. Each L.E.A.P.S. construct is composed of a T cell binding ligand (TCBL) which has previously demonstrated the ability to induce and elicit protective immunity and antigen specific antibody production in animal models. In CEL-SCI's L.E.A.P.S. swine flu vaccine the TCBLs will be coupled to three different highly conserved protective epitopes from three different essential proteins common to all influenza A virus strains.

L.E.A.P.S. technology is a novel T-cell modulation platform technology that enables CEL-SCI to design and synthesize proprietary immunogens. Any disease for which an antigenic sequence has been identified, such as infectious, parasitic, malignant or autoimmune diseases and allergies, are potential therapeutic or preventive sites for the application of L.E.A.P.S. technology.

About CEL-SCI Corporation

CEL-SCI Corporation is developing products that empower immune defenses. Its lead product is Multikine(R) which is being readied for a global Phase III trial in advanced primary head and neck cancer. CEL-SCI is also developing a vaccine to prevent and treat swine and other influenzas using its L.E.A.P.S. technology platform and expects to soon finish the validation of its state-of-the-art facility in Maryland which it expects to utilize to launch aseptic filling for stem cell produced therapies and other biological products. The Company has operations in Vienna, Virginia, and Baltimore, Maryl
'/>"/>

SOURCE CEL-SCI Corporation Copyright©2009 PR Newswire. All rights reserved

3 GOOD

Page: 1 2 3
Related medicine technology :

1. CEL-SCI to Present Data from Multikine Clinical Trials at National Institutes of Health (NIH), National Cancer Institute (NCI) Seminar Series
2. CEL-SCI Posts New Corporate Presentation to Website
3. CEL-SCI Corporation Releases Letter to Shareholders
4. CEL-SCI Corporation Releases Letter to Shareholders
5. CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine
6. CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect
7. CEL-SCI Expects to Take Delivery of New Manufacturing Facility on October 8, 2008
8. Data Suggest CEL-SCIs CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis
9. CEL-SCI Corporation Reports First Quarter Financial Results
10. CEL-SCI Corporation Announces 2007 Financial Results
11. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation